VX-548; 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
CAS: 2649467-58-1
Chemical Formula: C21H20F5N3O4
Molecular Weight: 473.4
Availability: R&D; Commercialization
⬤ CAS No.2649467-58-1
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | Suzetrigine |
| CAS No. | 2649467-58-1 |
| Chemical Formula | C21H20F5N3O4 |
| Molecular Weight | 473.4 |
| Related Categories | First-in-class non-opioid analgesic |
| Boiling Point | 591.8±50.0 °C(Predicted) |
| Density | 1.399±0.06 g/cm3(Predicted) |
| Solubility | Acetonitrile: Slightly Soluble: 0.1-1 mg/mlDMSO: Sparingly Soluble: 1-10 mg/ml |
| Acidity coefficient (pKa) | 11.74±0.70(Predicted) |
| Form | solid |
| Color | White to light yellow |
| Mechanism of Action | Suzetraline works by selectively inhibiting NaV1.8 channels, intervening in the pain signal transduction pathway and reducing pain before the signal reaches the brain. This mechanism of action blocks peripheral pathways and does not produce euphoria or excitement in the brain like opioids. |
| Application | VX-548 is an orally active and highly selective NaV1.8 inhibitor with analgesic effects. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).
Learn how to manage hazardous reactions during intermediate synthesis with risk assessment, process control, and safety management strategies.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
